PHARMACEUTICAL COMPOSITIONS FOR PREVENTING AND TREATING LUPUS NEPHRITIS COMPRISING SOLUBLE RAGE AS ACTIVE INGREDIENT
PURPOSE: The pharmaceutical composition for prevention or treatment of lupus nephritis including SRAGE as active ingredient is provided to show excellent effects of medical treatment in lupus nephritis by effectively reducing amount of proteinuria inside the textus renalis in immunocomplex deposition, and inside the concentrated blood serum claim -dsDNA antibody. CONSTITUTION: The pharmaceutical composition for prevention or treatment of lupus nephritis comprises the first sequence which unites ligand of receptor for advanced glycation end products: RAGE and soluble RAGE (sRAGE) as an active ingredient. The sRAGE of sequence listing first sequence obstructs bond between ligand of RAGE and RAGE. The sRAGE is combined with heavy chain of 7S antibody and Fc site of antibody The Fc site of antibody is Fc site of human immune globulin G1..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Europäisches Patentamt - (2018) vom: 27. Sept. Zur Gesamtaufnahme - year:2018 |
|---|
| Sprache: |
Unbestimmt |
|---|
| Beteiligte Personen: |
PARK YONG BEOM [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), Last update posted on www.epo.org: 2018-09-27, Last updated: 2021-03-11 |
|---|
| Patentnummer: |
KR20130083861 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA006607292 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA006607292 | ||
| 003 | DE-627 | ||
| 005 | 20230503184557.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210531s2018 xx |||||o 00| ||und c | ||
| 035 | |a (DE-627)EPA006607292 | ||
| 035 | |a (EPA)KR20130083861 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a und | ||
| 100 | 0 | |a PARK YONG BEOM |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a PHARMACEUTICAL COMPOSITIONS FOR PREVENTING AND TREATING LUPUS NEPHRITIS COMPRISING SOLUBLE RAGE AS ACTIVE INGREDIENT |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), Last update posted on www.epo.org: 2018-09-27, Last updated: 2021-03-11 | ||
| 520 | |a PURPOSE: The pharmaceutical composition for prevention or treatment of lupus nephritis including SRAGE as active ingredient is provided to show excellent effects of medical treatment in lupus nephritis by effectively reducing amount of proteinuria inside the textus renalis in immunocomplex deposition, and inside the concentrated blood serum claim -dsDNA antibody. CONSTITUTION: The pharmaceutical composition for prevention or treatment of lupus nephritis comprises the first sequence which unites ligand of receptor for advanced glycation end products: RAGE and soluble RAGE (sRAGE) as an active ingredient. The sRAGE of sequence listing first sequence obstructs bond between ligand of RAGE and RAGE. The sRAGE is combined with heavy chain of 7S antibody and Fc site of antibody The Fc site of antibody is Fc site of human immune globulin G1. | ||
| 650 | 4 | |a A61K | |
| 650 | 4 | |a che | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a LEE SANG WON |e verfasserin |4 aut | |
| 700 | 0 | |a CHOI DONG HOON |e verfasserin |4 aut | |
| 700 | 0 | |a PARK SUNG HA |e verfasserin |4 aut | |
| 700 | 0 | |a HONG SUNG YU |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2018) vom: 27. Sept. |
| 773 | 1 | 8 | |g year:2018 |g day:27 |g month:09 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/searchResults?DB=EPODOC&locale=en_EP&query=KR20130083861A |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | u | w | |j 2018 |b 27 |c 09 |
| 951 | |a AR | ||
| 952 | |j 2018 |b 27 |c 09 | ||